| INTRODUCTION
Adalimumab is a fully human anti-tumour necrosis factor (TNF) monoclonal antibody that is approved for multiple indications involving inflammatory processes, including rheumatoid arthritis, psoriasis, and inflammatory bowel disease.
1,2 Over the past decade, controlled clinical trials have demonstrated the efficacy of adalimumab for the induction 3 and maintenance of remission 3, 4 of moderate to severe
Crohn's disease (CD) in both TNF antagonist-naive 5 and experienced patients. 6 Similarly, clinical trial data support the use of adalimumab for induction 7, 8 and long-term maintenance of remission 7, 9 of moderate to severe ulcerative colitis (UC).
Global assessments of adalimumab demonstrate that it exhibits a safety profile typical of agents in the anti-TNF class. 10 11 whereas more limited safety data have been published for patients with UC. 9 The report on CD included data for 3160 patients (3402 PYs), 11 whereas no report encompassing the entire adalimumab clinical trial program for UC has been published. The safety profiles for adalimumab in patients with CD or UC were consistent across earlier and later reports and similar to the overall safety demonstrated in other indications. [9] [10] [11] The objective of the present analyses was to provide an update on the long-term safety profile of adalimumab in patients with CD or UC.
| MATERIALS AND METHODS

| Clinical trials
Safety data were evaluated for adult patients with CD or UC treated globally with adalimumab in phase 2/3, 3, and 3b trials, as well as their open-label extensions (Table 1 3-8, [12] [13] [14] [15] [16] [17] [18] [19] ); details of the study designs have been previously published. [3] [4] [5] [6] [7] [8] [12] [13] [14] [15] [16] [17] [18] [19] 
| Study population
Patients enrolled in the clinical trials were men and women 18-75 years of age (≥15 years in Japanese studies; no upper age limit in the M10-447 study), inclusive, with CD or UC confirmed by endoscopic or radiologic evaluation. Enrolled patients were required to have adequate cardiac, hepatic, and renal function. Patients were excluded because of underlying infection; cardiac, pulmonary, renal or hepatic dysfunction; pregnancy/breastfeeding; history of malignancy; and active or untreated tuberculosis (TB). All concomitant therapies were to be stable at baseline. The dose of concomitant corticosteroids could be tapered during the studies if patients responded to treatment, as assessed by the investigator; all other therapies (e.g., azathioprine, mercaptopurine, and methotrexate) were to remain stable throughout the study.
| Dosing
In the CD and UC studies, patients received placebo or adalimumab induction therapy for 4 weeks (adalimumab 80 mg at week 0 and 40 mg at week 2, or adalimumab 160 mg at week 0 and 80 mg at week 2), followed by placebo or maintenance adalimumab therapy 
| Adverse events
Treatment-emergent AEs were coded using the standardised international medical terminology provided in the Medical Dictionary for Regulatory Activities (MedDRA), version 18.1 (2015), and collected from the first dose (adalimumab or placebo) up to 70 days after the last dose or through the cut-off date of December 31, 2015. Previous studies addressing the adalimumab safety profile in patients with CD and UC used older versions of MedDRA. [9] [10] [11] AEs of interest were serious infections, opportunistic infections (excluding candidiasis and TB), malignant neoplasms, lymphomas, and injection site pain.
For a subanalysis of infections stratified by history of perianal disease, only studies with the "anal/peri-anal" check box on the medical history case report form were included. For a subanalysis of infections stratified by baseline perianal fistula, studies with "number of perianal fistulas" were included. 
| Statistical analysis
| Induction therapy
Incidences of most AEs of interest experienced by patients with CD and UC during double-blind induction therapy were comparable (CD and UC: any AEs, AEs leading to discontinuation, AEs leading to death, any infection, serious infection, opportunistic infection, malignancy, injection site pain) or lower (CD and UC: serious AEs) in the adalimumab groups vs the placebo groups (Table S1 ).
In patients with CD, the incidences of any AEs were significantly lower with double-blind adalimumab 160/80 mg compared with placebo (61% vs 72%, respectively; P = .010). One 72-year-old patient who received a second dose of adalimumab during the open-label induction period died of an AE (pulmonary embolus, as reported).
11
There were no opportunistic infections (excluding candidiasis and TB). One malignancy (small intestine carcinoma on day 2 of the study, as previously reported) 11 occurred with open-label 160/ 80 mg adalimumab therapy.
In patients with UC, the incidences of serious AEs during induction were significantly lower with either induction dose of adali- 3.4 | All adalimumab exposure
| Rates of AEs
In the all adalimumab exposure patients with CD and UC, infections represent the AE category with the highest rates, followed by serious AEs, AEs leading to discontinuation, and serious infections. The rates of any AEs, serious AEs, AEs leading to discontinuation, infections, serious infections, and injection site pain were numerically higher in patients with CD compared with patients with UC ( Table 2) . Rates of other AEs were low and comparable between the two populations.
In patients with ≥3 years of exposure, the same patterns were observed, and the rates of AEs were the same or numerically lower than the rates among the overall populations (Table S3 ).
In patients with CD, overall rates of infection were influenced by history of perianal disease (Table S4 ) and presence of perianal fistula at baseline (Table S5) . Patients with a history of perianal disease (n = 611; 466 PYs adalimumab exposure) vs without (n = 1851; 1236
PYs adalimumab exposure) had significantly higher rates of any infection (11.4 vs 7.5 events per 100 PYs, respectively; P = .019) and anal abscesses (4.1 vs 0.2 events per 100 PYs, respectively; P < .001) and numerically higher rates of perirectal abscesses (0.6 vs 0.2 events per 100 PYs, respectively; P = .233), peritonitis (0.6 vs <0.1 events per 100 PYs, respectively; P = .073), and rectal abscesses (0.6 vs 0.2 events per 100 PYs, respectively; P = .233) but numerically lower rates of pneumonia (0.4 vs 0.7 events per 100 PYs; P = .498). Rates of abdominal abscesses (0.9 and 1.0 events per 100 PYs, respectively)
were similar in patients with and without a history of perianal disease.
Similarly, patients with baseline perianal fistula (n = 499; 533
PYs adalimumab exposure) compared with patients without baseline perianal fistula (n = 2817; 2934 PYs adalimumab exposure) had significantly higher rates of any infections (12.2 vs 6.4 events per 100
PYs, respectively; P < .001), anal abscesses (3.9 vs 0.5 events per 100 PYs, respectively; P < .001), and rectal abscesses (0.8 vs 0.1 events per 100 PYs, respectively; P = .016). Patients with vs without perianal fistula at baseline had similar rates of pneumonia and abdominal abscesses.
Six adverse events of demyelinating disorder (0.1 events per 100
PYs) were reported in five patients with CD; two events were considered by investigators to be "probably related," three events to be "possibly related," and one event to be "unrelated" to adalimumab therapy. Two of six events of demyelinating disorder in patients with CD had alternative explanations that were independent of adalimumab therapy, including CD associated with optic neuritis and a previously uncharacterised demyelinating disease. Three events of demyelinating disorders (<0.1 events per 100 PYs) were reported in patients with UC. All events were considered by investigators to be "possibly related" or "probably related" to adalimumab therapy. One of the three events of demyelinating disorder had an alternative explanation: previously undiagnosed multiple sclerosis that predated adalimumab treatment.
| Opportunistic infections
Opportunistic infection rates (excluding oral candidiasis and TB) were 0.3 and 0.2 events per 100 PYs of adalimumab exposure for patients with CD and UC, respectively (Table S6) 
| Serious infections
Serious infection rates were 6.7 events per 100 PYs of adalimumab exposure in patients with CD and 3.5 events per 100 PYs in patients with UC (Table 3 ). The most common types of serious infections were abscesses, pneumonia and gastroenteritis for CD and pneumonia and appendicitis for UC. The rate of pneumonia (including bacterial pneumonia) was similar in patients with CD (0.5 events per 100
PYs) and UC (0.6 events per 100 PYs).
| Malignancies
The rate of malignancies was 1.2 and 1.0 events per 100 PYs in the CD and UC populations, respectively ( Table 4 ). The SIRs for most Adult UC F I G U R E 1 Standardised incidence ratios for adult patients with CD and UC treated with adalimumab. Ratios were calculated using a cut-off of events reported within 70 days after the last dose of adalimumab through 31 December 2014 (patients from the InspirADA study were not included in this analysis). A ratio <1 indicates that the observed number of malignancies was fewer than expected, based on estimates from a matched group in the general population from the SEER database, and was considered statistically significant if the 95% CI did not include the value 1. BCC, basal cell carcinoma; CD, Crohn's disease; NMSC, nonmelanoma skin cancer; SCC, squamous cell carcinoma; SEER, Surveillance, Epidemiology, and End Results Program of the National Cancer Institute; SIR, standardised incidence ratio; UC, ulcerative colitis matched controls from the general population (numerically different for female patients and statistically different for male patients).
| DISCUSSION
This large, comprehensive examination of adalimumab exposure in patients with CD or UC from the adalimumab clinical trial program confirmed the previously established safety profile. [9] [10] [11] Results from multiple studies demonstrated that adalimumab was well tolerated in patients with moderately to severely active CD or UC. No new safety signals were identified with prolonged adalimumab use in these patient groups compared with previous data and compared with other indications for adalimumab. [9] [10] [11] The rates for total observed malignancies were low for patients with CD or UC (≤1.2 events per 100 PYs in either population). SMRs of <1 observed in both patient populations indicated that the observed number of deaths was fewer than expected compared with a population matched for age and sex.
The most common AEs were infections. In patients with CD, the overall rate of infections was higher in patients with a history of perianal disease or baseline perianal fistula. No unexpected results
were observed for AEs of interest typical of anti-TNF agents.
Patients with CD or UC had low rates of demyelinating disorders (0.1 and <0.1, respectively).
The patients in these studies could receive immunosuppressant therapy and had moderate to severe disease activity, which would be expected to increase the risk of opportunistic infection. 11 Other studies have shown a contribution of combination therapy to infections (methotrexate in patients with rheumatoid arthritis, although not serious infections) 22 
